[Jak 3]This Could Massively Disrupt the $24.35 Billion NSAID Market

  As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, naproxen and other NSAIDs are effective, but can induce ulceration and bleeding of the digestive tract, with much higher incidence in patients, as noted by Antibe Therapeutics Inc. (TSX: ATE) (OTCQX: ATBPF). In these patients, COX-2 selective NSAIDs (e.g., celecoxib) offer only a modest improvement in terms of gastrointestinal safety, but their use is associated with significant cardiovascular toxicity. The good news, according to the company is that otenaproxesul, a hydrogen sulfide-releasing analog of naproxen is GI-safe when given to animals with compromised mucosal defense or pre-existing ulcers—situations in which selective COX-2 inhibitors cause ulcers and bleeding in humans.

  Plus, according to Antibe Therapeutics, “The U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for otenaproxesul, in development for the treatment of osteoarthritis pain. This enables Antibe to undertake human clinical trials in the U.S.; as previously announced, Antibe anticipates initiating its Phase III program later this year.”

  In addition to Antibe Therapeutics, other companies such as Trillium Therapeutics (NASDAQ:TRIL), Edesa Biotech Inc. (NASDAQ:EDSA), Aclaris Therapeutics Inc. (NASDAQ:ACRS), and Bristol-Myers Squibb Co. (NYSE:BMY) are looking for better, safer options, as well.

  Here’s More About Antibe Therapeutics Inc. (TSX: ATE)(OTCQX: ATBPF)

  Antibe Therapeutics Inc., a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property position for its current pipeline.

  “The robust data from the otenaproxesul’s extensive animal studies and human trials have highlighted the broad therapeutic and commercial potential of our drug platform,” commented Dan Legault, Antibe’s CEO. “As we prepare for otenaproxesul’s Phase III program, our strong balance sheet also enables us to tap Dalriada’s scientific expertise and throughput capacity to further our pipeline expansion strategy and IP position – efficiently and cost-effectively. This collaboration also leverages the projects already underway with our U.S. university-based chemistry group.”

  Dalriada is a contract research organization specializing in the development of small-molecule drugs (such as those based on Antibe’s platform) from initial discovery to development candidate nomination and management of IND-enabling studies. Its team comprises more than 50 scientists, including world-class experts in medicinal chemistry, bioanalytical chemistry, pharmacology, biochemistry and computational chemistry. Dalriada has supported integrated programs of public and venture capital-backed companies, including Janpix, Canopy Growth and Dunad Therapeutics.

  Dalriada’s efforts will extend medicinal chemistry capabilities and accelerate screening, selection and advancement of drug candidates for IND-enabling studies. As previously announced, Antibe’s first candidates for screening address inflammatory bowel disease, a condition affecting more than three million North American adults. Dalriada’s efforts are also being directed towards the development of fresh IP for existing pipeline drugs to lengthen the duration of patent and market protection. Antibe will retain ownership rights to any new IP.

  Diana Kraskouskaya, CEO of Dalriada, noted, “With the increasing recognition of inflammation’s central role in many diseases, we see the profound potential of Antibe’s revolutionary anti-inflammatory platform. Dalriada’s Turn-Key model is specifically designed to enable rapid expansion of therapeutic pipelines and accelerate value creation for our partners’ programs. We are excited to commit our resources to this undertaking in collaboration with Antibe’s world-renowned scientists and expert commercial team.”

  In support of these efforts, Antibe is pleased to appoint Harvey Schipper, MD, FRCPC, to its Scientific Advisory Board. A practicing physician, Dr. Schipper is also a professor of medicine and law at the University of Toronto. His efforts have shifted medical practice, scientific investigation and health policy around the world. In particular, Dr. Schipper’s pioneering work with the World Health Organization helped establish ‘Quality of Life’ as a substantive indicator of patient well-being. With a background also encompassing venture capital and business governance, he will spearhead efforts to uncover business opportunities by mapping unmet medical needs to scientific feasibility and commercial potential.

  Other related developments from around the markets include:

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported financial and operating results for the three months ended March 31, 2021. All financial amounts in this news release are in United States dollars, unless otherwise stated. “Coming off an R&D Day last week, we are very excited to have launched a new chapter in Trillium’s evolution,” said Jan Skvarka, Trillium’s President and CEO. “Building on a robust foundation anchored in a demonstrated monotherapy proof of concept of TTI-622 and TTI-621 in multiple lymphoma indications, we have initiated an ambitious Phase 1b/2 program in nine patient settings across hematologic and solid tumor cancers. With a major transformation program that touched literally every aspect of our identity completed in 2020, and approximately $276 million in cash, we are very well positioned to execute the recently initiated Phase 1b/2 program, and generate a robust flow of new data over the next couple of years.”

  Edesa Biotech Inc.,a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced the appointment of a key member to its management team to support the company’s expanding manufacturing activities. Rajan Puri has been appointed to the newly established position of Senior Vice President of Manufacturing. Mr. Puri is an expert in Chemistry, Manufacturing and Controls (CMC) in the biopharmaceutical field and will lead the company’s strategic planning and operations related to scale-up, manufacturing and quality control.

  Aclaris Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced positive preliminary topline results from its first in human Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy, safety, tolerability and pharmacokinetics of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in 50 subjects with moderate to severe atopic dermatitis (AD) (ATI-1777-AD-201). ATI-1777 is the second compound generated from Aclaris’ proprietary KINect? drug discovery platform to demonstrate positive proof of concept in clinical trials.

  Bristol-Myers Squibb Co. announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company. The dividend is payable on August 2, 2021 to stockholders of record at the close of business on July 2, 2021. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable September 1, 2021 to stockholders of record at the close of business on August 10, 2021.

  Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Antibe Therapeutics Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Antibe Therapeutics Inc. Please click here for full disclaimer.

  Contact Information: